DevelopmentsProduct News

UK’s NICE approves new injection medication for chronic migraine patients

- 1 in 7 people suffer from migraines in the Republic of Ireland - a condition which impacts as many as 700,000 people

  • Medication currently under review for approval for use in Irish patients
    • 1 in 7 people[1] suffer from migraines in the Republic of Ireland – a condition which impacts as many as 700,000 people[2]

The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new migraine medication for use by chronic migraine patients6.

The National Institute for Health and Care Excellence (NICE) has recommended AJOVY®     (fremanezumab) for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.

AJOVY® belongs to a class of medications called anti-CGRPs, which have been specifically designed to target the underlying causes of migraine.

The medicine can be self-injected either monthly or quarterly, once patients are trained by a Healthcare Professional3.

Current migraine prevention therapies include anti-epileptics, anti-depressants, beta blockers or onabotulinumtoxinA injections, however these were not developed specifically to target migraine4.

The majority of migraine sufferers have Migraine without Aura – common symptoms being an intense throbbing headache, usually on one side of the head, worsened by movement, and lasting from 4-72 hours5.  Other symptoms can include nausea, vomiting, sensitivity to light, noises and smells, stiffness of the neck and shoulders and blurred vision5

Research has shown that 1 in 71 people suffer from migraines in the Republic of Ireland – a condition which impacts as many as 700,0002 people overall.

In the Republic of Ireland, AJOVY® is currently being reviewed for use by the National Centre for Pharmacoeconomics (NCPE).

Show More

Related Articles

Close

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?